Commonly Used Quality of Life and Symptom Measurement Scales
On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.
On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.
Fatigue Symptoms Inventoty (FSI)
(Paul Jacobsen)
Multidimentional Fatigue Inventory (MFI-20)
(Ellen Smets and colleagues)
Brief Fatigue Inventory
(Charles Cleeland and colleagues)
Piper Fatigue Scale (PFS)
(Barbara Piper and colleagues)
FACIT-Fatigue Scale (Version 4)
(David Cella)
FACT-Anemia (FACT-An)
(David Cella)
EORTC: QLC-C30 (Version 3)
(Karen West)
Rotterdam Symprom Checklist
(Johanna de Haes and colleagues)
SWOG Quality of Life Questionaire
(Carol Moinpour and colleagues)
Quality of Life Index Cancer Version-III
(Carol Ferrans and Marjorie Powers)
CAncer Rehabilitation Evaluation System (CARES)
(Anne Coscarelli and Richard Heinrich)
Functional Living Index: Cancer (FLIC)
(Harvey Schipper abd Charles Olweny)
Quality of Life Index
(Cary Presant and colleagues)
L.A.S.A Scale and Quality of Lide Index Form: Form Q1
(Dianne Lindsay)
M.D. Ansderson Symptom Inventory (MDASI)
(Charles Cleeland)
McMaster Health Index Questionnaire
(Larry Chambers)
RAND 36-Item Health Survey 1.0 Questionnaire
(Judy Lewis)
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
